Protein A compositions and methods of use
View Patent ↗Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 μg.
1. A method for reducing an acute inflammatory response or inflammation in a subject, comprising administering to the subject a monomeric protein A (PA) composition comprising an effective amount of a monomeric protein A (PA), wherein the PA in the composition consists of monomeric protein A, sufficient to reduce the acute inflammatory response or inflammation mediated at least in part by an antibody in the subject.
2. The method of claim 1 , wherein the acute inflammatory response or inflammation mediated at least in part by an antibody is associated with myasthenia gravis, ulcerative colitis, Crohn's disease, psoriatic arthritis or pemphigus vulgaris.
3. A method for reducing an acute inflammatory response or inflammation in a subject, comprising administering to the subject a monomeric protein A (PA) composition comprising an effective amount of a monomeric protein A (PA), wherein the PA in the composition consists of monomeric protein A, wherein the acute inflammatory response or inflammation is associated with myasthenia gravis, ulcerative colitis, Crohn's disease, psoriatic arthritis or pemphigus vulgaris.
4. A method for reducing an acute inflammatory response or inflammation in a subject, comprising administering to the subject a monomeric protein A (PA) composition comprising an effective amount of a monomeric protein A (PA), wherein the PA in the composition consists of monomeric protein A, wherein the method results in a reduction in severity of a symptom of the acute inflammatory response or inflammation mediated at least in part by an antibody.
5. The method of claim 4 , wherein the symptom comprises swelling, pain, headache, fever, nausea, skeletal joint stiffness, or tissue or cell damage.
6. The method of claim 1 , wherein the antibody comprises one or more auto-antibodies.
7. The method of claim 2 , wherein the antibody comprises one or more auto-antibodies.
8. The method of claim 4 , wherein the antibody comprises one or more auto-antibodies.
9. The method of claim 1 , wherein the subject is a human.
10. The method of claim 2 , wherein the subject is a human.
11. The method of claim 4 , wherein the subject is a human.
12. The method of claim 1 , wherein the subject is a domestic animal.
13. The method of claim 2 , wherein the subject is a domestic animal.
14. The method of claim 4 , wherein the subject is a domestic animal.
15. The method of claim 1 , wherein the monomeric PA composition is administered systemically.
16. The method of claim 1 , wherein the monomeric PA composition is administered locally.
17. The method of claim 1 , wherein the monomeric PA composition is administered intravenously, intramuscularly, intraperitoneally, intradermally, subcutaneously, intracavity, intracranial, transdermally, parenterally, transmucosally or rectally.
18. The method of claim 3 , wherein the monomeric PA composition is administered systemically.
19. The method of claim 3 , wherein the monomeric PA composition is administered locally.
20. The method of claim 3 , wherein the monomeric PA composition is administered intravenously, intramuscularly, intraperitoneally, intradermally, subcutaneously, intracavity, intracranial, transdermally, parenterally, transmucosally or rectally.
21. The method of claim 1 , wherein the subject has idiopathic thrombocytopenia or autoimmune thrombocytopenic purpura.
22. The method of claim 21 , wherein the subject is a domestic animal in need of treatment.
23. The method of claim 1 , wherein the acute inflammatory response or inflammation is associated with myasthenia gravis.
24. The method of claim 1 , wherein the acute inflammatory response or inflammation is associated with ulcerative colitis.
25. The method of claim 1 , wherein the acute inflammatory response or inflammation is associated with Crohn's disease.
26. The method of claim 1 , wherein the acute inflammatory response or inflammation is associated with psoriatic arthritis.
27. The method of claim 1 , wherein the acute inflammatory response or inflammation is associated with pemphigus vulgaris.
28. The method of claim 3 , wherein the acute inflammatory response or inflammation is associated with myasthenia gravis.
29. The method of claim 3 , wherein the acute inflammatory response or inflammation is associated with ulcerative colitis.
30. The method of claim 3 , wherein the acute inflammatory response or inflammation is associated with Crohn's disease.
31. The method of claim 3 , wherein the acute inflammatory response or inflammation is associated with psoriatic arthritis.
32. The method of claim 3 , wherein the acute inflammatory response or inflammation is associated with pemphigus vulgaris.
33. The method of claim 4 , wherein the acute inflammatory response or inflammation is associated with myasthenia gravis.
34. The method of claim 4 , wherein the acute inflammatory response or inflammation is associated with ulcerative colitis.
35. The method of claim 4 , wherein the acute inflammatory response or inflammation is associated with Crohn's disease.
36. The method of claim 4 , wherein the acute inflammatory response or inflammation is associated with psoriatic arthritis.
37. The method of claim 4 , wherein the acute inflammatory response or inflammation is associated with pemphigus vulgaris.